CA2320226A1 - Methodes et compositions pour moduler l'activite de la leptine - Google Patents

Methodes et compositions pour moduler l'activite de la leptine Download PDF

Info

Publication number
CA2320226A1
CA2320226A1 CA002320226A CA2320226A CA2320226A1 CA 2320226 A1 CA2320226 A1 CA 2320226A1 CA 002320226 A CA002320226 A CA 002320226A CA 2320226 A CA2320226 A CA 2320226A CA 2320226 A1 CA2320226 A1 CA 2320226A1
Authority
CA
Canada
Prior art keywords
socs
leptin
activity
cells
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002320226A
Other languages
English (en)
Inventor
Jeffrey S. Flier
Christian Bjorbaek
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beth Israel Deaconess Medical Center Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2320226A1 publication Critical patent/CA2320226A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Psychiatry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

L'administration de leptine agit sur l'apport alimentaire et le poids corporel chez les humains et les animaux grâce à un mécanisme qui agit sur des zones spécifiques de l'hypothalamus. On a découvert que les gènes CIS-1, SOCS-1, SOCS-2, ET SOCS-3 produisent des effets antagonistes puissants sur l'action de la leptine. Dans des lignées cellulaires mammifères, le SOCS-3 bloque complètement la transduction de signal induite par la leptine, alors que les CIS, SOCS-1, et SOCS-2 restent sans effet. Le SOCS-3 constitue une cible importante de l'action de la leptine dans les cellules de l'hypothalamus sensibles à la leptine, ainsi qu'un inhibiteur puissant de la signalisation de la leptine. La hausse de l'activité du SOCS-3 dans des neurones sensibles à la leptine constitue un mécanisme potentiel de résistance à la leptine, observée dans les syndromes de l'obésité, les troubles de l'humeur, et les dysfonctionnements des fonctions reproductrices.
CA002320226A 1998-02-11 1999-02-10 Methodes et compositions pour moduler l'activite de la leptine Abandoned CA2320226A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US7432098P 1998-02-11 1998-02-11
US4427898A 1998-03-19 1998-03-19
US60/074,320 1998-03-19
US09/044,278 1998-03-19
PCT/US1999/002865 WO1999040946A2 (fr) 1998-02-11 1999-02-10 Methodes et compositions pour moduler l'activite de la leptine

Publications (1)

Publication Number Publication Date
CA2320226A1 true CA2320226A1 (fr) 1999-08-19

Family

ID=26721350

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002320226A Abandoned CA2320226A1 (fr) 1998-02-11 1999-02-10 Methodes et compositions pour moduler l'activite de la leptine

Country Status (5)

Country Link
EP (1) EP1053007A2 (fr)
JP (1) JP2002506004A (fr)
AU (1) AU2668699A (fr)
CA (1) CA2320226A1 (fr)
WO (1) WO1999040946A2 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2335107C (fr) 1998-07-28 2010-01-19 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Induction de genes a mediation par la leptine
US7078174B1 (en) 1998-12-21 2006-07-18 The Walter & Eliza Hall Institute Of Medical Research Screening methods using SOCS box-containing peptides
WO2000063357A2 (fr) * 1999-04-20 2000-10-26 Beth Israel Deaconess Medical Center Procedes et compositions permettant de moduler l'activite du facteur neurotrophique ciliaire
SE9903953D0 (sv) * 1999-11-01 1999-11-01 Sahltech Ab New use of the jak-stat system
AU2001240346B2 (en) * 2000-03-09 2006-09-14 The Walter And Eliza Hall Institute Of Medical Research Methods of regulating cytokine signalling
AUPQ614700A0 (en) * 2000-03-09 2000-03-30 Walter And Eliza Hall Institute Of Medical Research, The A method and agents useful for same
AU8178401A (en) 2000-05-22 2001-12-03 Vlaams Interuniv Inst Biotech Receptor-based interaction trap
ATE374213T1 (de) * 2000-11-14 2007-10-15 Vlaams Interuniv Inst Biotech Funktionelles fragment des leptinrezeptors
US7235629B2 (en) 2000-11-14 2007-06-26 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Functional fragment of the leptin receptor
AU2002950745A0 (en) * 2002-08-13 2002-09-12 The Walter And Eliza Hall Institute Of Medical Research A method and agents useful for same
US7423113B2 (en) 2004-08-25 2008-09-09 Vib Vzw Leptin antagonist
US7863240B2 (en) 2004-10-08 2011-01-04 Enzo Therapeutics, Inc. Methods and uses of leptin in hepatocellular carcinoma
US8969291B2 (en) 2004-10-08 2015-03-03 Enzo Therapeutics, Inc. Methods for decreasing leptin levels or activity for treating inflammation
US7575878B2 (en) 2004-11-18 2009-08-18 Vib Vzw Methods of inhibiting leptin-induced signaling with fibronectin III domain antibodies

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9608686A (pt) * 1995-05-30 1999-07-06 Smithkline Beecham Método para a detecção de compostos que modulam os efeitos da obesoproteína
AU5926296A (en) * 1996-05-21 1997-12-09 President And Fellows Of Harvard College Human cis protein
DK0948522T3 (da) * 1996-11-01 2008-09-22 Inst Medical W & E Hall Terapeutiske og diagnostiske midler, der kan modulere cellulær fölsomhed over for cytokiner
EP0970215A1 (fr) * 1997-11-03 2000-01-12 Incyte Pharmaceuticals, Inc. Suppresseur de la signalisation cytokinaire

Also Published As

Publication number Publication date
EP1053007A2 (fr) 2000-11-22
WO1999040946A3 (fr) 1999-10-28
AU2668699A (en) 1999-08-30
WO1999040946A2 (fr) 1999-08-19
JP2002506004A (ja) 2002-02-26

Similar Documents

Publication Publication Date Title
US6368826B1 (en) IGF-1 receptor interacting proteins
MXPA01007366A (es) Inhibidores de factores de crecimiento y diferenciacion y usos de los mismos.
CA2320226A1 (fr) Methodes et compositions pour moduler l'activite de la leptine
AU2006260088A1 (en) Novel physiological substance NESFATIN, substance relevant thereto, and use of the substances
WO1999015662A1 (fr) Facteurs de fixation des regions de repetition d'une proteine telomere et utilisation diagnostique et therapeutique de ces facteurs
US20020142466A1 (en) Methods and compositions for modulating ciliary neurotrophic factor activity
WO2000063357A9 (fr) Procedes et compositions permettant de moduler l'activite du facteur neurotrophique ciliaire
US20030219739A1 (en) Novel nucleic acid and polypeptide molecules
JP2009502208A (ja) エネルギーホメオスタシスに関係する新規ペプチド
US20040087530A1 (en) Methods and compositions for modulating leptin activity
US7635766B2 (en) Insulin-responsive DNA binding proteins-1 and methods to regulate insulin-responsive genes
JPWO2004018669A1 (ja) 塩誘導性キナーゼ２及びその用途
WO2000056756A2 (fr) Proteine de liaison de l'element regulateur de prolactine et son utilisation
US8354521B2 (en) Compositions and methods for inhibiting adipogenesis by inhibition of constitutive coactivator of ppargamma
EP1497305A2 (fr) Proteine 1 de liaison a l'adn sensible a l'insuline et methodes destinees a reguler des genes sensibles a l'insuline
US20060154864A1 (en) Transcript factor and an Akt substrate related to transcriptional action of insulin and applications of same
US20030158139A1 (en) Decreasing adipose mass by altering RSK2 activity
EP1228209B1 (fr) Proteine 1 de liaison de sequence d'adn reagissant a l'insuline et procedes de regulation de genes reagissant a l'insuline
US6593110B2 (en) Checkpoint-activating oligonucleotides
KR20080044205A (ko) 저산소 스트레스 응답에 관여하는 Int6 단백질, 및 그 용도
White et al. A Functional Interaction between RIP140
Rochford et al. ETO/MTG8 Is an Inhibitor of C/EBP
US20040053303A1 (en) Mahoganoid polypeptides, and related compositions and methods
JP2002533062A5 (fr)

Legal Events

Date Code Title Description
FZDE Dead